Reduce custom responses by refreshing standard responses for the highest-volume topics.
Budget vs actual spend
$22k
of $40k planned (55%)
Spend is in line with or behind elapsed time. Elapsed: 78%.
Late-by counts days between due date and completion, or due date and today for open milestones.
| Milestone | Due | Completed | Status | Timing | Late by | Evidence |
|---|---|---|---|---|---|---|
| Top 15 dosing/interaction responses identified | 15 May 2026 | 13 May 2026 | Completed | Completed on time | — | — |
| Responses refreshed and approved | 31 Aug 2026 | — | At risk | Overdue | 15 d | 9 of 15 approved; reviewer capacity |
Insights routed to this initiative.
Recurring MI question (14 in 60 days) on washout when switching from anti-CGRP mAbs; no standard response, driving cust…
Medical-information need · 08 Sept 2026
eGFR slope interpretation: request for data reported by renal pathologist (GB).
Evidence gap · 22 Jun 2026
Real-world persistence: gap in current materials reported by headache specialist (BR).
Treatment pathway · 17 May 2026
Sequencing after progression: request for data reported by thoracic medical oncologist (US).
Competitor activity · 03 May 2026
Patient-reported outcomes: practice variation observed reported by community nephrologist (GB).
Education need · 17 Apr 2026
Switching between CGRP agents: request for data reported by headache specialist (IT).
Health economics · 21 Feb 2026
Actions whose result record is this initiative.
Lumeva MI SLA breaches increase as switching inquiries grow without a standard response.
P 3 × I 3 = 9 · Medical information · Fatima Al-Sayed · due 10 Oct 2026
Same objective (SO-LMV-03)
Same objective (SO-LMV-03)
Same objective (SO-LMV-03)
| Task | Assignee | Due | Priority | Status |
|---|---|---|---|---|
| Approve remaining 6 Lumeva standard responses | EMDr. Elena Moretti | 25 Sept 2026 | Medium | In progress |
No audit events for this record
Audit events are written when the record is created, changed, approved, signed or exported.
Data lineage